CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has secured key intellectual property (IP) for RNAi applications in vaccine development by completing an exclusive option agreement with Mount Sinai School of Medicine in New York City and an exclusive license agreement with The University of Queensland in Brisbane, Australia. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in many human diseases, including infectious disease and cancer.
